Mereo BioPharma, under pressure from an activist investor, has reduced its head count to stretch its cash runway out into the second quarter of 2025. The biotech disclosed the cuts in a rebuttal to Rubric Capital Management’s “low-risk strategy” for unlocking the value of its assets while preserving cash. Source: Fierce Biotech 01/09/2022